KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Finished Goods (2016 - 2022)

TherapeuticsMD's Finished Goods history spans 11 years, with the latest figure at $4.5 million for Q3 2022.

  • For Q3 2022, Finished Goods rose 42.36% year-over-year to $4.5 million; the TTM value through Sep 2022 reached $4.5 million, up 42.36%, while the annual FY2021 figure was $2.9 million, 12.3% down from the prior year.
  • Finished Goods reached $4.5 million in Q3 2022 per TXMD's latest filing, up from $4.0 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $5.0 million in Q3 2019 to a low of $1.6 million in Q1 2018.
  • Average Finished Goods over 5 years is $3.4 million, with a median of $3.3 million recorded in 2019.
  • Peak YoY movement for Finished Goods: surged 122.24% in 2019, then tumbled 41.45% in 2021.
  • A 5-year view of Finished Goods shows it stood at $2.9 million in 2018, then soared by 71.09% to $5.0 million in 2019, then plummeted by 32.69% to $3.4 million in 2020, then decreased by 12.3% to $2.9 million in 2021, then skyrocketed by 54.42% to $4.5 million in 2022.
  • Per Business Quant, the three most recent readings for TXMD's Finished Goods are $4.5 million (Q3 2022), $4.0 million (Q2 2022), and $3.3 million (Q1 2022).